Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 13, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 18, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001225208-26-002134
Filed / recorded
Feb 18, 2026, 10:58 PM UTC
Added to OQRO
Oct 2, 2026, 12:27 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
BOSTON SCIENTIFIC CORP
Issuer CIK
885725
Ticker
BSX
Reporting person
Joseph Michael Fitzgerald
Relationship
Officer
Officer title
EVP & Group Pres, Cardiology
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Feb 13, 2026
Transaction code
A
Shares / units
34,898
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
204,790
Ownership form
Direct
Amendment
No
Footnotes from the filing
On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
Congress trade